Best mode for treating hard cataracts

Article

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

Liu Yizhi, MD, PhD of the Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou, China and colleagues assessed the effects on "hard" cataracts of the "multiburst" and "shortburst" settings of the Sovereign phaco machine (AMO) in comparison to the settings on the Whitestar technology platform (AMO).

The differences between the three groups were statistically significant. The ultrasonic power was highest for the Whitestar, followed by Sovereign's shortpulse and then the multiburst setting. The multiburst setting had the highest ultrasonic power release time, effective phaco time and rate of endothelial cell loss; the group displaying the lowest levels of these variables was the Whitestar group. In the multiburst group, there was also one case of wound burn and three eyes displaying abnormal fluctuations in the anterior chamber depth.

Based on these data, the research team concluded that, while Sovereign's multiburst mode was an unreliable method of performing this type of surgery, Whitestar technology had the best results of the study and offers an acceptable alternative.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.